针对新抗原的TCR工程T细胞免疫疗法:当前的进展和挑战
Zhi Pang1,2, Man-Man Lu3, Yu Zhang3
1Liver Cancer Institute, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Biomarker research
|December 1, 2023
概括
T细胞受体工程T细胞 (TCR-T) 疗法对癌症有希望,但在固体瘤中面临挑战. 在新抗原查和解决瘤微环境方面的进展是个性化TCR-T疗法的关键.
科学领域:
- 免疫学和癌症治疗疗法
- 细胞和分子瘤学 细胞和分子瘤学
背景情况:
- 使用T细胞受体工程T细胞 (TCR-T) 的采用细胞疗法是一种正在发展中的癌症治疗策略.
- TCR-T疗法旨在利用自然的T细胞受体 (TCR) 多样性来向瘤特异性抗原.
- 目前TCR-T疗法的临床结果,特别是在固体瘤中,仍然不理想,这表明存在重大挑战.
研究的目的:
- 审查基于TCR结构的抗原识别和信号机制.
- 描述最近在新抗原识别和特定TCR查技术方面的进展.
- 总结正在进行的临床试验,并讨论个性化TCR-T治疗的挑战和未来方向.
主要方法:
- 审查关于TCR结构,抗原识别和信号通路的现有文献.
- 分析最近在新抗原发现和TCR查方面的技术进步.
- 来自正在进行的临床试验的数据汇编和总结,涉及针对新抗原的TCR-T疗法.
主要成果:
- 在有效选瘤特异性抗原及其相应的TCRs方面,TCR-T疗法面临着障碍.
- 关键的挑战包括病毒载体安全性,TCR不匹配,以及免疫抑制瘤微环境.
- 在理解TCR抗原相互作用和开发查技术方面取得了进展.
结论:
- 个性化TCR-T疗法在癌症治疗方面具有显著的潜力.
- 克服与抗原发现,TCR特异性和瘤微环境相关的挑战对于治疗成功至关重要.
- 未来的研究应该专注于创新策略,以提高TCR-T细胞基础免疫疗法的疗效和安全性.
更多相关视频
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
539
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
11.7K
相关概念视频
01:27Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
01:22T Cell Activation and Clonal Selection
743
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
743
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K